Rifampin (rifampin)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Rifampin is a rifamycin B-derivative antibiotic active against mycobacteria and some gram-positive and -negative bacteria.
USES: This medication is used to prevent and treat tuberculosis and other bacterial infections. Rifampin belongs to a class of drugs known as rifamycin antibiotics. It works by stopping the growth of bacteria.
This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.
Generic name: rifampin
Pronunciation: (rif-AM-pin)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Rifampin
Indications
The following indications are listed for Rifampin:
- Active Tuberculosis
- Inactive Tuberculosis
- Meningococcal Carrier
- Prevention Of Meningococcal Meningitis
Also known as: Active Tb, Acute Tuberculosis, Asymptomatic Carrier Of Meningococcus, Asymptomatic Neisseria Meningitidis Carrier, Latent Tuberculosis, Prevention Of Cns Meningococcal Disease.
Dosing
Dosage of rifampin is identical for oral and IV administration.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
An increased incidence of congenital malformations (principally spina bifida and cleft palate) has been reported in the offspring of mice and rats given rifampin in a dosage of 150-250 mg/kg daily during pregnancy. The incidence of these anomalies was dose dependent. In addition, imperfect osteogenesis and embryotoxicity occurred when rifampin doses up to 20 times the usual daily human dose were used in pregnant rabbits. The manufacturer states that isolated cases of fetal malformations have been reported. Although safe use of the drugs during pregnancy has not been definitely established, rifampin (combined with isoniazid and/or ethambutol) has been used to treat clinical tuberculosis in pregnant women. There are no adequate and controlled studies to date using rifampin in pregnant women, and the drug should be used during pregnancy only when the potential benefits justify the possible risks to the fetus. The American Thoracic Society (ATS), US Centers for Disease Control and Prevention (CDC), and Infectious Diseases Society of America (IDSA) state that rifampin is considered safe for use in pregnant women. The manufacturer states that neonates of rifampin-treated mothers should be carefully observed for evidence of adverse reactions.
Since rifampin is distributed into milk and because animal studies indicate that the drug has a potential for tumorigenic effects, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.